S. Readers are cautioned that
actual results are subject to a number of risks and uncertainties, including
the availability of funds and resources to pursue R+D projects, the successful
and timely completion of clinical studies , the ability of Spectral to take
advantage of business opportunities in the biomedical industry, the granting
of necessary approvals by regulatory authorities as well as general economic,
market and business conditions, and could differ materially from what is
currently expected. Based on recent positive interim result, Genentech further
plans filing of a sBLA. Data implicate that SU11248 can
overcome Gleevec resistance in patients with metastatic GIST.

metachromatic cleidocranial

com/cgi-bin/prnh/20040820/RESEARCH )
The gross majority of all drugs, which reach late stage of development,
are someway or another passed on to the large pharmaceutical companies because
they hold the capital needed to conduct the expensive clinical trials as well
as the regulatory commitment needed to gain an approval. This
report provides you with update information on the most recent advances made
and the competitive struggle that exists between the large pharmaceutical
companies. Iressa in May 2003 and Tarceva in November 2004. The fact
that Tarceva demonstrate an improved survival benefit in advanced NSCLC
patients the competitive situation is presently swinging away from Iressa and
in favor for Tarceva. The anticipation of an accelerated
approval is the results of a study comparing Thalomid plus dexamethasone to
dexamethasone alone in previously untreated multiple myeloma patients.

hamartoma mcardle

Spectral is committed to developing diagnostics for the most
critical public health concerns including sepsis, myocardial infarction, and
emerging infectious diseases". Avastin as well as Erbitux were
both approved as treatment for colorectal cancer whereas Alimta was approved
as treatment for mesothelioma. During 2004 Celgene received FDA approvable letter
for Thalomid sNDA in multiple myeloma.

myocardial madelung

Centers for Disease Control about 1 in 150 patients
infected with WNV will develop a serious infection such as encephalitis or
meningitis which can result in paralysis or even death.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws.researchandmarkets.
Moreover, the marketed drug Iressa already on the market has been added to
American Society of Clinical Oncology Clinical Practice guidelines.

moyamoya mcardle

mannosidosis rokitansky

Dr.
West Nile Virus infection is a mosquito borne seasonal illness that is
known to have infected tens of thousands of patients in North America since
its emergence in the last several years. A potential threat for Aromasin is AstraZenecas drug Faslodex, which
has been shown to be at least as effective as anastrozole and associated with
a longer median duration of response. Preliminary results further suggest that the
combination of PTK787 with FOLFIRI as an option in patients with metastatic
colorectal cancer .com
Fax: +353 1 4100 980

metachromatic mcardle

states and Canadian provinces.
Contents covered include the following:

- Approval and New Development of Erbitux
- Two Drugs at War; Iressa versus Tarceva
- Breast Cancer Competition
- European Approval for Estrogen Receptor Downregulator
- Dual Kinase Inhibitor with Improved Effect in Breast Cancer
- Side effects + resistance
- Epothilone B analogues in Patients with Breast/Prostate Cancer
- Avastin safety warning unlikely limit use
- FDA backs drug for lung cancer treatment
- Late Stage Cancer Vaccine Back To The Bench
- Discontinued Phase III Studies: NSCLC
- New Therapeutic Option for Patients with Renal Cell Carcinoma
- Fast Track Status in Advanced Renal Cell Carcinoma
- Option For The Treatment of Colorectal Cancer
- New Drug to Replace Standard Chemotherapy in Colon Cancer?
- A Drug More Potent than Camptothecin
- Additional Revenues for Gleevec
- Overcoming Gleevec resistance
- Reactivating DNA-damaging in hypoxic tumors
- New agent with antimyeloma activity

For more information visit
http://www.

brucellosis microphthalmia

Spectral Diagnostics and IDx report the successful result of a pivotal clinical trial of a new rapid assay for West Nile Virus infection

TORONTO, April 7 - Spectral Diagnostics Inc. Spectral manufactures the EAA(TM) and
Cardiac STATus(R). Four
FDA approvals were also reported during 2004. Even though FDA
issued a warning that Avastin could increase the risk of stroke the prognosis
is that Avastin is going to be combined with a wide range of 5FU-based
chemotherapies.
Drugs that will be of future interest are the niche of overcoming Gleevec
resistance. Several research reports have been published in this field during
the most recent years and we might expect this field to become a highly
competitive area.

moyamoya woltmann

syringomyelia microsporidiosis

The development of this assay demonstrates the
successful partnership model of Spectral and IDx to develop new diagnostic
tools to aid clinicians in making important decisions that affect patient
management. Pfizers
drug Aromasin has been reported to improve disease-free survival and to be
superior to Tamoxifen as a first line hormonal treatment for metastatic breast
cancer. Moreover, the
addition of SU11248 to AML chemotherapy regimens could result in improved
treatment results.

mononucleosis brucellosis

Research and Markets: Providing Update Information on the Most Recent Advances Made and the Competitive Struggle That Exists Between the Large Pharmaceutical C

In turn, Orphan Drug Status was granted to BAY 43-9006 for renal
cancer, PI-88 for melanoma and Revlimid for myelodysplastic syndromes.
As regard the treatment of colorectal cancer, several drugs are candidates
to change the standard therapy.com/reports/c16537

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.

moyamoya hamartoma

Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted therapy. While these assumptions were considered reasonable by Spectral at the time
of preparation, they may prove to be incorrect.
(Logo: http://www. And very recently, Tarceva was approved as
monotherapy to treat non-small cell lung cancer. Both drugs target the human epidermal
growth factor receptor 1 and have in near term gained FDA approval as
treatments of NSCLC.

cleidocranial woltmann

New products include rapid diagnostics for
sepsis (the Endotoxin Activity Assay).newscom.

mononucleosis papulosis

(TSX:
SDI) and its joint venture research and development company, IDx Inc .S.
To date, Spectral's WNV diagnostics is the only rapid point of care test
for WNV developed that is intended for individual patient by patient
application at the time of their presentation to the physician.
Dr.
Hallmarks of 2004 includes that BAY 43-9006 and CCI-779 were granted Fast
Track Designition for treating patients with renal cell carcinoma.

woltmann spinocerebellar

We remain on schedule
with our regulatory strategy to submit this test for consideration to Canadian
and U. West Nile Virus has
caused over 400 deaths in the U. A drug that in near term has been suggested to overcome
Gleevec resistance is Pfizers SU11248.

mononucleosis mannosidosis

Spectral's common shares are listed on The Toronto Stock
Exchange: SDI.

com/reports/c16537 ) has announced the addition
of Large Pharma: 2004 A Year of Progress to their offering.
The year 2004 has been a year of competitive challenge for AstraZenacas
drug Iresssa and Genetechs drug Tarceva. This indicates that a competitive
situation is imminent between Pfizer and AstraZeneca. Xeloda is suggested as a replacement of 5-
FU/LV in the adjuvant therapy of colon cancer.

sanfilippo myelitis

The study demonstrated that the WNV rapid assay
has a high degree of sensitivity and specificity for the rapid diagnosis of
WNV exposure in patients at risk. alone over the last 2 years and has been
found in almost all U. Two of the drugs,
Aromasin and Faslodex both block the effects of the estrogen hormone. Edotecarin has been shown to be
more potent than SN-38.
Beside above candidates developed by the large pharmaceutical companies,
Celgenes thalidomide analogs are under intense investigations as a new agent
with antimyeloma activity.
Therapeutic candidates included in this analysis: Alimta, Aromasin,
Avastin, Bay 43-9006, BMS-247550, CCI-779 , Edotecarin, Erbitux, Faslodex,
Gleevec, Herceptin, IMC-BEC2, Iressa, Lapatinib, MelVax, PTK787, Sarasar,
SU011248, Tarceva, Thalomid (+thalidomide analogs) Tirapazamine and Xeloda.

sanfilippo paresthetica

Joseph Keffer , Chief Scientist and Managing Director of IDx
commented, "We look forward to continuing to partner with Spectral in making
advanced testing available particularly in areas of critical diagnosis.researchandmarkets .

rokitansky syringomyelia

,
announced today that its novel rapid assay for West Nile Virus (WNV) infection
has met the primary endpoints of a pivotal clinical trial conducted by a major
U.

brucellosis mononucleosis

regulators to allow physicians to access this test in time for the
2005 WNV summer season.
Spectral is a developer of innovative technologies for comprehensive
disease management. DUBLIN, Ireland, Research and Markets
(http://www.

madelung sainton

Many patients with West Nile Virus
infection will have non-specific symptoms of fever, headache, malaise , or
other flu-like symptoms that are difficult for physicians to diagnose.S.
Current products are rapid format tests measuring markers of myocardial
infarction (Cardiac STATus test).

hamartoma paresthetica

public health laboratory. We are
initiating another test in the West Nile Virus family of important infections
as well as other novel tests". Implicit in this information, particularly in
respect of the completion of the proposed offering, the future outlook of
Spectral and anticipated events or results, are assumptions based on beliefs
of Spectral's senior management as well as information currently available to
it .

infarction mononucleosis

S. Paul Walker, MD, PhD, CEO of Spectral stated, "this successful study
marks the conclusion of the development phase of Spectral's novel rapid assay
for detecting human infection with the West Nile Virus.
According to the U. In this report
progress is analysed that is made by the large pharmaceutical companies top
oncology drug candidates whom have reached Phase III clinical evaluation. However, Genentechs drug Avastin is still held in high
regard as the drug with the largest single sales potential .

madelung microphthalmia

Fast Track
Designition were also awarded to Xcytrin for treating patients brain
metastases.
Several drugs that are in Phase III are evaluated for treatment of breast
cancer. Even though most candidates have been on the market for some years we
do see substantial progress in this field .

mannosidosis microsporidiosis